|
|
|
|
|
|
|
Poorly Soluble Drugs
How can we improve
dissolution, solubility and bioavailability? |
|
15th - 16th April 2009,
The Lakeside Centre, Aston University, Birmingham, UK |
|
|
|
Programme:
[Wednesday]
[Thursday]
|
|
Wednesday
15th April |
|
10.00 |
|
Setting the Scene,
aims of workshop and introduction
Yvonne Perrie,
Aston University
Thomas Rades, University of Otago, New Zealand |
|
|
10.10 |
|
The role of
biopharmaceutical properties in defining formulation strategies for
poorly soluble drugs
Balvinder Vig, Bristol-Meyers Squibb |
|
|
10.50 |
|
The principles
governing solubility and bioavailablity
Juergen
Siepmann, Lille, France |
|
11.30 |
|
Coffee |
|
12.00 |
|
Predicting
solubility from stuctures
John Delaney,
Syngenta |
|
|
12.40 |
|
Formulation
considerations - Salt Selection
Barbara
Conway, Aston University |
|
13.20 |
|
Lunch |
|
14.20 |
|
Increasing
solubility by crystal engineering and co-crystal formulation
Tomislav
Friscic, University of Cambridge |
|
|
15.00 |
|
Improving the
dissolution properties of poorly soluble drugs using hot melt extrusion
Gavin Andrews,
Queens University, Belfast |
|
15.40 |
|
Coffee |
|
16.10 |
|
Increasing the
solubility using solid solutions
Thomas Rades,
University of Otago, New Zealand |
|
|
16.50 |
|
Close |
|
19.00 |
|
Evening Dinner |
|
| |
|
|
|
Thursday
16th April |
| 09.30 |
|
Pharmaceutical
applications of Cyclodextrins: Basic science and formulation development
Thorsteinn
Loftsonn, Reykjavik, Iceland |
|
|
10.10 |
|
CMC, toxicology and
marketed drug development of Cyclodextrins
Marcus
Brewster, Johnson & Johnson, Belgium |
| 10.50 |
|
Coffee |
|
11.20 |
|
Increasing the
solubility using lipsomes
Yvonne Perrie,
Aston University |
|
|
12.00 |
|
Delivering low
solubility drugs using solid lipid nanosuspensions
Heike Bunjes,
Carolo-Wilhelming University, Germany |
|
12.40 |
|
Lunch |
|
13.40 |
|
Increasing
solubility using micelles and microemulsions
Jayne
Lawrence, King's College London |
|
|
14.20 |
|
Polymeric
bioavailability enhancers
Ijeoma
Uchegbu, University of London |
|
15.00 |
|
Coffee |
|
15.20 |
|
Early formulation
considerations for poorly soluble drugs
Kathryn Hill,
AstraZeneca |
|
|
16.00 |
|
Testing formulation
for poorly soluble drugs
Mike Pollit,
Merck |
|
|
16.40 |
|
Final Discussion and Close |
|
| |
|
BACK TO EVENT OPTIONS |
|
|
